<?xml version = '1.0' encoding = 'UTF-8'?><STUDY_SET>
   <STUDY accession="ERP107358" alias="ena-STUDY-POL-08-03-2018-02:58:30:643-65" center_name="POL" broker_name="EGA">
      <IDENTIFIERS>
         <PRIMARY_ID>ERP107358</PRIMARY_ID>
         <SUBMITTER_ID namespace="POL">ena-STUDY-POL-08-03-2018-02:58:30:643-65</SUBMITTER_ID>
      </IDENTIFIERS>
      <DESCRIPTOR>
         <STUDY_TITLE>2015_AML_ETO_WGS_additional</STUDY_TITLE>
         <STUDY_ABSTRACT>This study includes 2 paired samples of 2015 Korean AML-ETO paitients. 2 AML-ETO tumor samples are paired with each normal(Saliva or BM derived) sequencing data.The results of this WGS study were analyzed by Mutect and GATK for ranking germline variants and cancer variants to make mutational profile matrix.</STUDY_ABSTRACT>
         <STUDY_DESCRIPTION>This study includes 2 paired samples of 2015 Korean AML-ETO paitients. 2 AML-ETO tumor samples are paired with each normal(Saliva or BM derived) sequencing data.The results of this WGS study were analyzed by Mutect and GATK for ranking germline variants and cancer variants to make mutational profile matrix.</STUDY_DESCRIPTION>
         <CENTER_PROJECT_NAME>2015_AML_WGS_additional</CENTER_PROJECT_NAME>
         <STUDY_TYPE existing_study_type="Other"/>
      </DESCRIPTOR>
   </STUDY>
</STUDY_SET>